Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis
Corey Cutler(Harvard University), Karen K. Ballen(University of Virginia Health System), H T Kim(Dana-Farber Cancer Institute), John Koreth(Otsuka (Japan)), Deborah Liney(Dana-Farber Cancer Institute), Thomas R. Spitzer(Harvard University), Vanessa P. Ho(Dana-Farber Cancer Institute), Joseph H. Antin(Dana-Farber Cancer Institute), María Herrera(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Julia A. Brown(Cornell University), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Kristen E. Stevenson(Dana-Farber Cancer Institute), Carol Reynolds(Harvard University), RJ Soiffer(Harvard University), B Dey(Harvard University), Sean M. McDonough(Harvard University), Phillippe Armand(Harvard University), Jerome Ritz(Dana-Farber Cancer Institute), G. Kao(Dana-Farber Cancer Institute), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 110
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k